Cancer-testis gene expression is associated with the methylenetetrahydrofolate reductase 677 C > T polymorphism in non-small cell lung carcinoma

Creative Commons License

Senses K. M., Gonen M., Barutcu A. R., Kalaylioglu Z. I., Isbilen M., KONU KARAKAYALI Ö., ...More

BMC MEDICAL GENETICS, vol.14, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2013
  • Doi Number: 10.1186/1471-2350-14-97
  • Journal Name: BMC MEDICAL GENETICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Cancer-testis genes, 1-carbon pathway, Adomet, DNA methylation, METHIONINE SYNTHASE REDUCTASE, DNA METHYLATION, RISK, HYPOMETHYLATION, DEREPRESSION, VARIANTS, BORIS, MTHFR, CTCF
  • Middle East Technical University Affiliated: Yes

Abstract

Background: Tumor-specific, coordinate expression of cancer-testis (CT) genes, mapping to the X chromosome, is observed in more than 60% of non-small cell lung cancer (NSCLC) patients. Although CT gene expression has been unequivocally related to DNA demethylation of promoter regions, the underlying mechanism leading to loss of promoter methylation remains elusive. Polymorphisms of enzymes within the 1-carbon pathway have been shown to affect S-adenosyl methionine (SAM) production, which is the sole methyl donor in the cell. Allelic variants of several enzymes within this pathway have been associated with altered SAM levels either directly, or indirectly as reflected by altered levels of SAH and Homocysteine levels, and altered levels of DNA methylation. We, therefore, asked whether the five most commonly occurring polymorphisms in four of the enzymes in the 1-carbon pathway associated with CT gene expression status in patients with NSCLC.